Retatrutide

Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Adding the glucagon receptor on top of what tirzepatide already does is the key differentiator. Early trial data showed weight loss results exceeding both semaglutide and tirzepatide, with some participants losing over 24% of body weight.

It's still in clinical trials and not yet FDA-approved. Dosing in the trials ranged from 1 mg to 12 mg weekly. Because it's newer, there's less real-world data on long-term use compared to semaglutide or tirzepatide.

Based on Phase 2 trial data, appetite suppression shows up in the first week or two. Weight loss results at 48 weeks were striking, with the 12 mg group averaging around 24% body weight loss.

The glucagon receptor component may also contribute to increased energy expenditure, which is something semaglutide and tirzepatide don't directly do. Since it's still in trials, real-world timelines are less established. Expect a similar ramp-up period as the other GLP-1 class drugs.

GI side effects dominate again: nausea, diarrhea, vomiting, constipation. The trial data showed these were mostly mild to moderate and decreased over time. Increased heart rate was reported in some participants, likely related to the glucagon receptor activity.

Because it's pre-approval, the long-term safety profile is less understood than semaglutide or tirzepatide. Something to factor in.

Refrigerate at 36 to 46°F. Reconstitute with bacteriostatic water, swirl gently. Same general handling as other lyophilized peptides. Good for about 28 days once reconstituted.